Amalgamated Bank Sells Shares of Amphastar Pharmaceuticals,

August 12, 2023

☀️Trending News

Amalgamated Bank has recently announced the sale of shares of Amphastar Pharmaceuticals ($NASDAQ:AMPH), Inc. through Defense World. Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing, manufacturing and selling generic and branded prescription drugs, active pharmaceutical ingredients, and drug delivery systems. The company has developed a wide range of generic drugs and active pharmaceutical ingredients. They specialize in developing novel formulations, manufacturing processes and drug delivery systems. The company also has a number of branded drugs in their portfolio.

It is known for its reliable quality standards and strong customer base. As Amalgamated Bank has sold shares of Amphastar Pharmaceuticals, Inc. through Defense World, investors have the opportunity to gain exposure to this growing biopharmaceutical sector. The company’s established track record of success and dedication to innovation make it an attractive choice for long-term investors.

Market Price

Amphastar’s stock opened at $62.7 and managed to close at $63.1, up by 0.4% from its last closing price of $62.8. After the news of the sale broke, it witnessed a gradual increase in the share price. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Amphastar Pharmaceuticals. More…

    Total Revenues Net Income Net Margin
    540.89 101.94 18.8%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Amphastar Pharmaceuticals. More…

    Operations Investing Financing
    78.8 -32.78 -26.44
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Amphastar Pharmaceuticals. More…

    Total Assets Total Liabilities Book Value Per Share
    1.38k 789.03 12.21
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Amphastar Pharmaceuticals are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    17.4% 169.4% 25.0%
    FCF Margin ROE ROA
    9.5% 14.9% 6.1%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    GoodWhale provides a comprehensive financial analysis of AMPHASTAR PHARMACEUTICALS. Our Risk Rating indicates that the company is a medium risk investment from both a financial and business standpoint. We have also identified two risk warnings on their balance sheet for non-financial factors. If you would like to take a more in-depth look at our analysis, we invite you to register with us. Our analysis will help you make informed decisions about investing in AMPHASTAR PHARMACEUTICALS. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The competition between Amphastar Pharmaceuticals Inc and its competitors Mallinckrodt PLC, Avadel Pharmaceuticals PLC, RPG Life Sciences Ltd is fierce. All four companies are constantly trying to one-up each other in the race to create new and innovative drugs. This competition is good for the consumer, as it drives down prices and forces the companies to be constantly innovating.

    – Mallinckrodt PLC ($NASDAQ:AVDL)

    Avadel Pharmaceuticals PLC is a pharmaceutical company with a market capitalization of 356.22 million as of 2022. The company’s return on equity is -255.63%. Avadel Pharmaceuticals PLC is engaged in the development, manufacture, and commercialization of pharmaceutical products. The company’s products include drugs for the treatment of sleep disorders, urinary incontinence, and attention deficit hyperactivity disorder.

    – Avadel Pharmaceuticals PLC ($BSE:532983)

    Life sciences is the study of living organisms, including plants, animals, and human beings. The company’s market cap is 14.42B as of 2022, a Return on Equity of 19.69%. The company focuses on the research and development of new drugs and therapies to treat diseases.


    Amphastar Pharmaceuticals, Inc. is a growing biopharmaceutical company that develops, manufactures, and markets generic and branded injectable and inhalation products. Analysts suggest that the company has an attractive pipeline of innovative products and possess a strong financial position with significant cash reserves. Furthermore, it is expected that Amphastar’s presence in the generic injectable and inhalation markets will continue to expand in the future.

    Additionally, the company has established strategic collaborations with leading healthcare companies that are expected to drive new opportunities in the near future. All in all, Amphastar Pharmaceuticals, Inc. seems to be an attractive long-term investment for investors with an appetite for risk.

    Recent Posts

    Leave a Comment